Home > News > PerkinElmer Expands Presence in China with New Technology Center in Shanghai

  •   PerkinElmer Expands Presence in China with New Technology Center in Shanghai

  • Center Will Consolidate Three Shanghai Locations
  • Furthers PerkinElmer’s Commitment to Growing China Market

BOSTON, MA -- February 21, 2006 -- PerkinElmer Inc. (NYSE: PKI), a global leader in Heath Sciences and Photonics, today announced the opening of a new technology center in Shanghai, China, that will expand the company’s presence in that country and consolidate three current Shanghai locations. The center will bring together PerkinElmer’s sales, service, customer care and technology support functions, and also serve as the company’s regional headquarters for greater China.

“The new Technology Center furthers PerkinElmer’s commitment to expanding in China, which is a rapidly growing market for health sciences and photonics technologies,” said Gregory L. Summe, PerkinElmer chairman and chief executive officer. “Our business units will benefit from greater leverage of technical and customer support resources, consolidated materials sourcing, and close proximity to key customers whose needs drive our product innovation.”

The new Technology Center is located at Zhangjiang Bio-Pharma Park in Pudong New Territory, Shanghai, China. In addition to accommodating PerkinElmer’s current operations, the space allows for easy expansion to support further product and application development.


Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our ability to identify a purchaser of the Company’s semiconductor business, negotiate and consummate the sale of such business, including obtaining regulatory approvals; (2) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (3) risks related to our failure to introduce new products in a timely manner; (4) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (5) a delay in resolution of the Company’s tax audits and an adverse determination with respect to the Company’s tax audits by the Internal Revenue Service or other taxing authorities; (6) cyclical downturns continuing to affect several of the industries into which we sell our products; (7) our ability to adjust our operations to address unexpected changes; (8) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (9) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (10) competition; (11) regulatory compliance; (12) regulatory changes; (13) our failure to obtain and enforce intellectual property protection; (14) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (15) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.


About PerkinElmer PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of its customers' needs, PerkinElmer creates innovative solutions - backed by unparalleled service and support - for customers in health sciences, semiconductor, aerospace, and other markets whose applications demand absolute precision and speed. The Company markets in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.


For Further Information
Investor Contact Media Contact
Steven Delahunt
PerkinElmer, Inc.
+1 (781) 431-4258
Kevin Lorenc
PerkinElmer, Inc.
+1 (203) 402-6890